Quantum Pharmaceutical is the leading manufacturer and supplier of unlicensed medicines and special obtains. With a current portfolio of over 30,000 products, and 7 years manufacturing experience, we provide the widest range of unlicensed medicines and special obtain lines in the UK, making us the only true ‘one-stop-shop’ in the Specials industry.

In addition to our extensive product range, we also offer unrivalled turnaround times. Our 8am to 10pm opening hours enable us to process manufactured lines up until 6pm and stocked lines up until 9pm for delivery next day by noon. We are able to accept orders either by phone, fax, e-mail or via our online ordering portal. This flexible approach allows our customers to place their orders using their preferred method at a time convenient to them.

Our primary focus is quality and consistency and we are continuously expanding our product portfolio in order to satisfy individual patient needs and our innovations in product development and service delivery allow us to lead customer expectations in this crucial area. We have a combined quality assurance team of 34 people, 21 of whom are pharmacists on hand to assist customers with technical support and advice.


Quantum Pharma Plc

First Day of Dealings on AIM - 11 December 2014



http://www.quantumpharma.co.uk/

Quantum Pharma PLC (AIM:QP.) admitted to AIM. Read about it on the Investor’s Champion blog http://tinyurl.com/kq43z9m

Pre-close Trading Update
RNS
RNS Number : 3528E
Quantum Pharma PLC
09 February 2015








9 February 2015




Quantum Pharma Plc

("Quantum", the "Company" or the "Group")



Pre-close Trading Update



Quantum Pharma Plc (AIM: QP.), a growing manufacturer, supplier and service provider to the niche pharmaceutical sector, today announces its pre-close trading update for the financial year ended 31 January 2015.



The Board is pleased to announce that Quantum has made progress across all areas of its business in the last financial year, with strong performance in the final quarter, and the Board expects adjusted EBITDA and adjusted profit before tax for the full year to be comfortably ahead of market expectations.



The Group's core business, Quantum Pharmaceutical, continued to increase its customer base across the unlicensed medicine and Special Obtains market, maintaining its position as the clear market leader in this sector. As announced on 29 December 2014, Quantum Pharmaceutical secured an exclusive three year supply agreement with Bestway Panacea Healthcare Limited (whose 774 stores currently trade under the Co-operative Pharmacy name).



Colonis, the specialist pharmaceutical product development business, reached a significant milestone by launching its first licensed medicine, Aviticol 20,000 IU capsules, having received a licence on 18 December 2014. Colonis continues to develop its pipeline of potential licensed medicines and has now submitted a further six dossiers to the MHRA, which are progressing through the licensing process.



U L Medicines, Biodose and Quantum Aseptics Services continue to develop in line with management's expectations and all enjoyed record final quarters.





Quantum will announce its Preliminary Results for the year ended 31 January 2015 in May 2015.



Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "This has been a transformational year for Quantum with good progress made across all areas of the Group and Colonis reaching a very significant milestone with the launch of its first licensed medicine. We were delighted with the support we received from our new shareholders on the successful IPO in December and we look to the future with confidence."



- Ends -

This one looks a good one and it's hitting new highs (though it's not been around long).
Announced they'll be comfortably head for results due May.
Loads of big buys of late.
I've been buying plenty last few days.
Tuck away and forget.

Shares -

Analysts at broker Zeus Capital forecast a £6.5 million pre-tax profit, reversing the £2.6 million loss it made in the previous financial year. Zeus Capital forecasts the company will post a £12.7 million pre-tax profit in the financial period ending 31 January 2016.


Momentum is building and with new products and contracts expected Quantum is set to report strong profit growth in the coming years.

Acquisition
RNS
RNS Number : 5035K
Quantum Pharma PLC
17 April 2015








17 April 2015




Quantum Pharma Plc

("Quantum" or the "Group")



Acquisition of Lamda companies for €9.7 million



Quantum Pharma Plc (AIM: QP.), a growing manufacturer, supplier and service provider to the niche pharmaceutical and healthcare sector, is pleased to announce the acquisition of 100 per cent of the share capital of Lamda (UK) Limited, Lamda Laboratories SA and Lamda Pharmaceuticals SA, collectively 'Lamda' (the "Acquisition") for a total consideration of €9.7 million.



Lamda is a pharmaceutical development and licensing business with customers in the UK, Germany, Italy, Scandinavia and Greece. Lamda provide a fully outsourced research and development service to companies looking to license medicinal products from its state of the art development laboratories near Athens, Greece.



Lamda has a proven track record of product development and licensing, having completed in excess of 100 projects during which Lamda has accumulated both IP and dossiers which the Board believe can be commercialised with the support of the Group. The first product that the Group has identified will be submitted to the MHRA for assessment within the next month.



Lamda has filed 11 patent applications, including six patents granted in Greece, three pending in Greece, and two pending in Europe and other countries.



The Lamda entities generated combined revenues of €2.1 million and losses of €0.14 million for their respective 2014 financial periods. The consideration due in respect of the acquisition of Lamda totals €9.7million, including €4.7 million payable on completion and €5.0 million deferred, to be paid in two equal instalments 12 and 24 months after completion of the acquisition. The consideration will be paid out of the Group's cash reserves.



The acquisition of Lamda has a strong strategic rationale for a number of reasons:



· Lamda has a strong pipeline of products in development including a number of niche pharmaceutical products to be filed with European Regulators shortly. This is complementary as it further strengthens the Group's pipeline of products which is already in place within Colonis.



· The Board believe there is substantial latent value in the 100 plus projects that Lamda has already completed and that a number of these novel products can be readily commercialised via out-licensing to selected third parties in a number of territories.



· Lamda's international network will be used as a platform to enable the Group's other business units to penetrate overseas markets.



· The activities of Lamda are complementary to those of the Group, as it provides vertical integration through the addition of in-house product development capability. Once integrated Lamda is expected to deliver synergies both financially and operationally.



Lamda significantly increases the Group's current product development portfolio by both number of products and therapeutic area.



Since the Group's admission to AIM, Colonis has made good progress, launching its first licensed product, Aviticol, as well as having a further licence granted on a product which is awaiting market launch in Q2 2015. A further six products are currently in assessment with the MHRA. In addition, several new products have been added to the short-term pipeline.



Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "The acquisition of Lamda represents an important and exciting milestone for the Group and a further deployment of the funds raised at the time of our admission to AIM in December 2014 in accordance with the Group's stated strategy. The addition of Lamda to the Group will be earnings enhancing from early 2016 and provides us with a significantly enlarged product portfolio, with latent value as well as in-house development capability. By adding further vertical integration to Quantum it gives the Group even more control over speed of delivery as well as cost levels whilst maintaining our high standards of customer service. Lamda also gives us a footprint in Europe which we can use as a platform for overseas expansion."



- Ends -

New high and chart breakout. Looking good for blue sky.

Can't say like this one...121p IMHO, far too expensive for a new AIM business and I don't see any pharma-approvals. Very glossy back-slapping website and reference latest acquisition - looks like growing their turnover - Only rarely does this add lasting value.
Then there is their bla on Charity raising efforts - very fine indeed, so long as it's outside working time- - - Don't let's forget Northern Rock had 20 pages DYOR, showing how good they were at sponsoring and only a paragraph on "risks" - really showed where NRK Management was falsely-focussed. HuH!
EDIT ( 2%Nov2016(0 it's up from 34p low at 43p, but shows the inflated opening prices were too high..... is it really value now?

mr market massively disagrees and loves them. Look at the volume on the breakout!!

quantum-pharma-growth-prospects-not-priced

Final Results

Midas SHARE-TIPS-Quantum-Pharmaceutical-devises-prompts-people-medicine-alerts-carers-need-arises

Quantum Pharma PLC (QP.:LSE) set a new 52-week high during today's trading session when it reached 169.00. Over this period, the share price is up 76.41%.

Pre-close Trading Statement & Notice of Results
RNS
RNS Number : 5558W
Quantum Pharma PLC
20 August 2015







20 August 2015

Quantum Pharma Plc

("Quantum" or the "Group")



Pre-close Trading Statement

and

Notice of Half Year Results



Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce its pre-close trading update for the half year ended 31 July 2015.



The Board is pleased to announce that Quantum has made good strategic progress across all areas of its business in the last six months. Trading for the Group remains in line with market expectations for the year to 31 January 2016.



As previously announced Quantum completed the acquisitions of the Lamda group of companies and NuPharm Group during this period. The Board is confident that these businesses will add value to the Group in the future.



Colonis, the specialist pharmaceutical product development business, continues to grow its pipeline and submissions to the relevant authorities and to progress its product launch programme:



· over 70 regulated products (licensed products and medical devices) are now in the pipeline with a number of other opportunities to increase the pipeline further during this financial year (May 2015: 60 regulated products).

· 16 products are in for assessment with the MHRA and other authorities for registration. That number is expected to be at least 28 by the end of this financial year.

· two products have been launched in the market (one licensed product and one medical device). The second licensed product is manufactured and awaiting final release permission from the MHRA to enter the market. It is anticipated that this will be received by the end of September.

· 11 regulated products are expected to have been launched by the end of the financial year. There are also a number of active opportunities for additional regulated products to be brought into the pipeline and launched this year.



The Board remains confident that licences will be achieved for all products submitted for assessment to the relevant regulators although, in respect of a small number of applications made earlier in the year, this is taking longer than expected.



Quantum will announce its half year results for the six months ended 31 July 2015 on Tuesday 20 October 2015.



Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "The first six months of the financial year have been a busy period at Quantum Pharma. We successfully completed the strategic acquisitions of Lamda and NuPharm and the integration of both these companies into the Group is ongoing. In addition, pleasingly, a number of the business units have had record half years.



Progress continues to be made on the Colonis pipeline, and we look forward to announcing a number of further regulated product launches during the second half of the year. As is sometimes the case, the regulatory process on certain products is taking slightly longer than anticipated, however we are confident of securing licences for all products in assessment with the MHRA and other regulators. We look forward to presenting our half year results in October."





- Ends -

20 Aug N+1 Singer 177.00 Buy

Quantum Pharma announces major contract
RNS
RNS Number : 5918Z
Quantum Pharma PLC
21 September 2015







Press Release
21 September 2015






Quantum Pharma Plc

("Quantum" or the "Group")



Quantum Pharma announces major Biodose® Services contract



Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce the first large-scale NHS homecare contract win for its Biodose Services division. Following a competitive tender process, Biodose Services have been awarded an 18 month contract with Yorkshire and Humber NHS Pharmaceutical Purchasing Consortium ("YHPPC"), with an option to extend for a further two years by mutual consent.

Biodose Services provides pre-prepared medication regimes to care homes and delivery of medication to the home. This contract is to supply nearly 3,000 patients with medicines including antiretrovirals, anti-tuberculosis medication, medicines for cystic fibrosis, and oral chemotherapy medication, which will require 9,500 deliveries to individuals per annum. Biodose Services' expects to commence delivery in Q4 of 2015, and will reach full capacity within six months.

This contract marks a continuation of the progress seen by Biodose Services in the last year, following a contract agreed in June 2015 with The Newcastle upon Tyne Hospitals NHS Foundation Trust to supply arthritis medication to a number of patients, as well as operating the Stork Facility Service, providing homecare services to 1,200 patients (both private and NHS) per month.



The Group expects this contract to significantly increase turnover within the Biodose Services division, and make a modest contribution to group profitability, for the financial year ending 31 January 2017.



Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "This contract shows the strength of the Biodose Services offering, which along with our Biodose® devices, aims to not only reduce the burden placed on the NHS by medication non-compliance, but also, allow patients to remain within a familiar environment, rather than spending unnecessary time in hospital. This contract provides an excellent platform to drive further penetration of Biodose®, and in-time Biodose Connect® (our telehealth product), as well as to identify further niche medicines to add to our growing development pipeline. I am pleased by the progress shown by Biodose Services within the last year and look forward to working with the Yorkshire and Humber NHS Pharmaceutical Purchasing Consortium to explore further opportunities across our business units."



- Ends -

Quantum Pharma announces Lamda out-licensing
RNS
RNS Number : 3111C
Quantum Pharma PLC
15 October 2015







Press Release
15 October 2015






Quantum Pharma Plc

("Quantum" or the "Group")



Quantum Pharma announces Lamda out-licensing agreements



Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce a succession of out-licensing deals across Europe from its recently acquired division, Lamda.



A generic plus dossier containing an undisclosed Active Pharmaceutical Ingredient ("API"), which Lamda co-developed, has been out-licensed to a French-based pharmaceutical company in over 40 territories from which Lamda is receiving licensing fees and rights to future royalty income.



Lamda has also out-licensed a generic dossier for an undisclosed API to a pharmaceutical company for a fixed license fee with a royalty over five years once the product is licensed in Germany.



The continued commercialisation of the latent value held within Lamda's 100 plus projects is encouraging, and Quantum believes that Lamda will continue to develop as described at the time of acquisition.



Andrew Scaife, CEO of Quantum Pharma, said: "At the time of acquisition we stated that part of the upside potential within Lamda was its ability to out-licence products, and these initial two European out-licensing deals demonstrate that. These out-licences see Quantum's stated business plan for Lamda developing as anticipated, and we expect to see further deals in the coming months. Since IPO, Quantum has significantly diversified both its product portfolio and its infrastructure, and with this has come a number of potential new income streams and an increased platform of strategic partners in Europe."







- Ends -

Half year results

Mucodis� Medical Device Launch
RNS
RNS Number : 6148E
Quantum Pharma PLC
05 November 2015







Press Release
5 November 2015




Quantum Pharma Plc



("Quantum" or the "Group")



Mucodis® Medical Device Launch



Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that Colonis, part of its newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat some of the side effects of cancer treatment in patients.



This range initially comprises up to seven products that are used to treat the side effects of chemotherapy and radiotherapy, specifically the inflammation of different mucosal membranes of the body, including that of the mouth and rectum. The range will be marketed and sold in the UK under the Mucodis® brand name.



Some 330,000 patients in the UK are diagnosed with cancer every year and most suffer painful or unpleasant side effects as they progress with treatment. The Mucodis® range provides the NHS with prescribable products for a number of associated conditions, including mucositis, dermatitis and proctitis. Colonis has been granted an exclusive distribution licence for these products for five years, with an option to extend beyond this initial period.



The first product in the range, Mucodis® Oromucosal Spray for the treatment of oral mucositis, a painful inflammation of the mouth that can follow certain typical cancer treatments, is launched today, with a preventative mouthwash expected to follow later this financial year. Of the 330,000 new instances of cancer in the UK every year, approximately 132,000 (40%) patients will typically develop some degree of oral mucositis as a result of standard treatment therapies. This figure is higher in paediatric oncology patients (90% of patients), as well as in patients receiving irradiation for neck and head cancers (97% of patients). Previously there have been limited options to manage this side effect. It is anticipated that additional Mucodis® products will be launched in the next financial year.



To support the launch of this range of products, Quantum has a specific therapeutic sales team in place, which has been active amongst oncology specialists, nurses and pharmacists establishing demand for these products. As a result of this, the entire first manufacturing batch of Mucodis® Oromucosal Spray has been bought by the pharmaceutical wholesale chain to ensure access for these prescribers.


Andy Scaife, CEO of Quantum Pharma, commented: "We are excited to be making available the first product in the Mucodis® range. This range has the potential to make a difference for patients living with the side effects of cancer treatment commonly triggered by radiotherapy and chemotherapy. The launch of Mucodis® and the developments within this team mark a promising new chapter for both Niche Pharmaceuticals and the Group's expansion into regulated products, with a number of further medical device and licensed product launches anticipated during the current financial year."









- Ends -

MEET THE TECH SUPERSTARS OF TOMORROW

A 12-month share price performance of the companies that presented at the Innovators & Investors Forum last year included:

Elecosoft +42%
Idox +22%
Instem +34%
KBC Advanced +45%
XL Media +41%

The Innovators & Investors Forum, organised in partnership with Cenkos Securities and SHARES, is in its 4th year and is the UK's only technology investment show.

REGISTER NOW

Thousands of investors have attended our previous shows, attendees will also benefit from:

Learning from industry experts and influencers about the markets, the technology sector and individual companies
Find out from fund managers how they view the future in 2016
Meet the directors of up to 30 listed technology focused companies
Listen to our expert team of SHARES journalists

The event is supported with an extensive conference program
Keynote Speakers:

Daniel Coatsworth, Editor - Shares
Mark Dunne, Growth Companies Reporter - SHARES
Steven Frazer, Online Editor - SHARES
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Gervais Williams, MD - Miton Group

Further speakers to be announced soon.

Meet the teams and talk directly to CEOs and Directors from:


Advanced Oncotherapy
Abzena
Advanced Oncotherapy
ANGLE
Brady
CML Microsystems
Cyan
Eckoh
eg solutions
Flowgroup
Ilika
Instem
Kromek
Lombard Risk
Mirada
Plastics Capital
Quantum Pharma
Rosslyn Data Technologies
Selftrade
SHARES
TyraTech

Further companies to be announced soon.




Date: 2nd February 2016

Venue: Business Design Centre, London


Event timings

Registration: from 09:00
Conference: 09:45 - 17:00
Exhibition: 09:00 - 18:00



REGISTER NOW